Adipocyte cell therapy targeting BMP signaling alleviates fibroadipose tissue deposition in secondary lymphedema
Molecular Therapy · 2025
DOI: 10.1016/j.ymthe.2025.09.034 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy, 2025. Verfasst von Ziyu Chen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA; Peking University Shenzhen Hospital, Shenzhen,…. Hauptthemen laut MEDLINE: Bone Morphogenetic Proteins, Signal Transduction, Adipocytes, Lymphedema. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, National Natural Science Foundation of China, National Institutes of Health.
Abstract (Originalsprache)
Secondary lymphedema is a chronic disease affecting an isolated limb following lymph node resection for cancer treatment. Management options are limited and onerous, leading to near-universal progression to subcutaneous fibroadipose tissue deposition. Here, we identify bone morphogenetic protein (BMP) ligands as mediators of fibroadipose tissue deposition through in vitro experiments with human lymphedema fluid and BMP-specific inhibitor. Systemic in vivo delivery of BMP inhibitor reduces fibroadipose tissue deposition in a mouse model of hindlimb secondary lymphedema. Considering systemic delivery may be undesirable for an anatomically isolated disease, we engineered a cell therapy using purified adipocytes, aiming for clinical translation in a resource- and time-constrained environment requiring only mechanical manipulation. We then devised a strategy for gene delivery into adipocytes and verified the secretion of the recombinant peptide inhibitor of BMP ligands. Upon in vivo delivery of the engineered adipocytes, we verified secretion of the BMP inhibitor and a reduction in fibroadipose tissue deposition in the mouse hindlimb. Our findings highlight BMPs as signaling mediators for fibroadipose tissue deposition and provide a blueprint for a cell therapy using genetically modified adipocytes for local drug delivery. This approach may be in a point-of-care strategy and potentially be amenable to various conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA; Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, China.
- Department of Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
- Harvard School of Dental Medicine, Boston, MA 02115, USA.
- Department of Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA. Electronic address: sagarwal15@bwh.harvard.edu.
Förderung
- NIAMS NIH HHS
- National Natural Science Foundation of China
- National Institutes of Health
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
Zitieren
APA
Chen, Z., Wu, M., Nagam Hanumantharao, S., Koirala, P., Akbari Ghavimi, S. A., Siegel, A. E., Liu, C., Taylor, E., Broyles, J., Sinha, I., Rosen, V., & Agarwal, S. (2025). Adipocyte cell therapy targeting BMP signaling alleviates fibroadipose tissue deposition in secondary lymphedema. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2025.09.034
Vancouver
Chen Z, Wu M, Nagam Hanumantharao S, Koirala P, Akbari Ghavimi SA, Siegel AE, et al. Adipocyte cell therapy targeting BMP signaling alleviates fibroadipose tissue deposition in secondary lymphedema. Molecular Therapy. 2025. doi:10.1016/j.ymthe.2025.09.034
BibTeX
@article{Chen2025,
author = {Chen, Ziyu and Wu, Mengfan and Nagam Hanumantharao, Samerender and Koirala, Pratik and Akbari Ghavimi, Soheila Ali and Siegel, Ashley E and Liu, Chang and Taylor, Erin and Broyles, Justin and Sinha, Indranil and Rosen, Vicki and Agarwal, Shailesh},
title = {Adipocyte cell therapy targeting BMP signaling alleviates fibroadipose tissue deposition in secondary lymphedema},
journal = {Molecular Therapy},
year = {2025},
doi = {10.1016/j.ymthe.2025.09.034}
}
EUVIMED